The foundational discovery of the toxic alpha-sheet structure was first identified via computer simulations because it was impossible to characterize experimentally. This computational hypothesis then required 15 years of wet lab work to validate, highlighting the power of in-silico methods to pioneer novel drug targets.

Alt-Pep sees its core strength as early-stage science and development across a portfolio of amyloid diseases. The company's long-term plan is to focus on this R&D engine and partner with big pharma for late-stage development and commercialization, rather than building its own sales and marketing infrastructure.

The degradation mechanism is fundamentally superior to inhibition because it removes the entire protein, addressing both its enzymatic and scaffolding functions. This allows degraders to hit targets harder and more completely, suggesting they could become the dominant modality across oncology and other therapeutic areas.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.

Instead of patenting a specific molecule, Alt-Pep underwent a decade-long process to patent the novel alpha-sheet protein structure itself. This unconventional IP strategy gives them a powerful, defensible platform applicable across numerous amyloid diseases, not just a single target composition.

Alt-Pep's SOBA blood test is a crucial companion diagnostic for its SOBIN-AD therapeutic. It allows for patient stratification by confirming the presence of the drug's target—toxic oligomers. This creates a rare, direct link between biomarker, target, and mechanism, significantly increasing the probability of clinical success.

A single degrader molecule can destroy thousands of target proteins per hour, a massive improvement over the 1-to-1 stoichiometry of traditional inhibitors. This extreme potency makes them ideal payloads for Degrader-Antibody Conjugates (DACs), combining the precision of antibodies with the power of catalytic degradation.

The long-term vision for Alt-Pep's diagnostic extends beyond symptomatic patients or those with family histories. The goal is for it to become a routine screening assay, administered annually to the general population to catch the disease at its earliest molecular stages, changing the paradigm from treatment to prevention.